BIOSENIC announced that it has appointed Lieven Huysse, MD, as permanent Chief Medical Officer (CMO), effective 17 April 2023. Lieven Huysse will succeed Michel Wurm's, MD, who was appointed as CMO ad interim to drive forward the development of BioSenic's platforms. Michel has been a key element in the development of Medsenic and BioSenic during the last 18 months. Lieven will be responsible for continued progression of both BioSenic late-stage assets: The ALLOB MSC platform using cells with immune privilege, anti-inflammatory properties and the ability to differentiate into bone tissues when injected into the specific bone sites to be regenerated or repaired.

The Phase 2b trial of ALLOB, a randomized, double-blind, placebo-controlled study in patients with high-risk tibial fractures, will report decisive key results in Second Quarter 2023. Lieven will help progress this trial to conclusion. This includes overall responsibility for liaising with the CRO nominated for the trial and liaising with investigators in the thirty-five trial centers across seven EU countries.

For the autoimmune ATO platform, Lieven will also be focused on the start of the Phase 3 trial in cGvHD, as well as the Phase 2b trials in systemic lupus, and systemic sclerosis. Lieven has been selected as CMO for his extensive expertise in the biopharma and medical device industries. This includes the managing multi-center international clinical studies, including pre-market approval studies for submission to regulatory authorities including the US FDA, reimbursement authorities and Key Opinion Leaders management.

He has gained over eight years of experience in immunology, as well as in the diabetes, allergy, cardiovascular and psychiatry sectors. He has 17 years of experience in the medical device sector with knee, hip and spine, as well as with trauma, cardiovascular and endovascular products. He has held senior leadership positions in a number of European headquarters, including in Belgium, Switzerland, Spain and the Netherlands.

He has served as CMO for Anaconda Biomed S.L., senior director of medical affairs at Intrinsic Therapeutics Inc., director of clinical and regulatory affairs at Wright Medical EMEA (now Microport®), medical director for Menarini Group, global brand medical manager for Switzerland-based UCB Farchim, manager clinical Affairs EMEA at Stryker Corp. and Medical Advisor EMEA at Janssen.